Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Nature|August 13, 2013
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersGeorgia Hatzivassiliou, Jacob R Haling, Huifen Chen, et al.
Nature|February 5, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthGeorgia Hatzivassiliou, Kyung Song, Ivana Yen, et al.
Plos One|October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Molecular Cancer Therapeutics|October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayJeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Plos One|January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2021
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeuticIñaki Etxeberria, Elixabet Bolaños, Alvaro Teijeira, et al.
Journal of Medicinal Chemistry|January 18, 2014
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitorsSteven T Staben, Jianwen A Feng, Karen Lyle, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
Pageof 6